Friday 19 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Concepta - manufacturing deal signed in China: launch now very close: URGENT warrant deadline

By HotStockRockets | Monday 3 October 2016

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

We tipped these shares at a 12p offer - they are now 19.5p-21p but hang on tight. We aim to be selling at 25p+ very soon. But before then an urgent reminder for long term holders: warrants! Deadline 6 October.

There were warrants at 7.5p handed out to those who owned shares before the RTO earlier this year. 1 warrant for every share held. The number of warrants outstanding is pretty small but given where the shares now stand it would be sheer insanity not to exercise now as the deadline is 6 October. We got our broker to exercise ours (which equated to c3.5% of the total number of warrants) last week and we remind all long term holders not to let this free money opportunity lapse. Call your broker today if you are unsure. 

Last week Concepta (CPT) announced that it has signed a deal with a Chinese company, Huanzhong Biotech Limited ( HZ) to to assemble and package Concepta's 'My Lotus' fertility product. My Lotus already has regulatory clearance and so this paves the way for a launch very soon indeed. In fact we believe that the first kits have already been shipped.

Concepta states:

HZ Biotech will exclusively assemble and package Concepta produced components (including bulk tests and electronic meters), to produce Concepta's My Lotus product to specification for the Chinese market. HZ will utilise its manufacturing site and processes, adhering to locally applicable laws and Chinese regulatory requirements.

In addition to assembling the final My Lotus product, HZ Biotech will be the sole purchaser of Concepta's My Lotus product and help facilitate its launch to the Chinese market and include post-market surveillance. Concepta will also look to work with a network of distributors in China to help achieve maximum market penetration in China and will update the market on these developments in due course.

Concepta's MyLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.


Concepta states that an estimated 4 million women in China each year discover that they have unexplained infertility and that as such annual revenue potential for this target market is "expected to be worth" £250m per annum. Hmmmm, poor English. We think that means that the market potential is £250 million per annum. But if My Lotus is as good as Concepta claims then it does not need much of a market share to justify a big premium to the current share price - at 19.5p the market cap is c £20 million.

And that is just China. 2016 will see a launch in the PRC. In 2017 we will see launches in the UK and Europe.

We expect more news on all fronts well before Christmas. You can see the potential and you can see that it is far from discounted. We are well up on the share tip ( at a 12p offer) but on this news the stance is strong hold. On this website we continue to target 25p + to sell and to target that for well before Christmas.

In fact we hope to see the shares zooming past 25p very soon indeed. News of the first Chinese sales must be released very soon and we think that the RNS pipeline is pregnant with other developments.

To catch the next share tip from HotStockRockets out shortly  for just £5 click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on CPT


Comments are turned off for this article.

Site by Everywhen